目的 探討心脈通膠囊聯(lián)合曲美他嗪治療不穩(wěn)定型心絞痛的臨床效果。方法 選取2016年7月—2019年7月渭南市中心醫(yī)院收治的不穩(wěn)定型心絞痛患者130例，隨機(jī)分成對照組（65例）和治療組（65例）。對照組進(jìn)餐同時(shí)口服鹽酸曲美他嗪片，20 mg/次，3次/d。治療組在對照組基礎(chǔ)上口服心脈通膠囊，3粒/次，3次/d。兩組患者均連續(xù)治療4周。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者心絞痛發(fā)作情況、心肌缺血總負(fù)荷（TIB）、SAQ評分，及血清髓過氧化物酶（MPO）、血清N末端B型利鈉肽原（NT-proBNP）和血管內(nèi)皮生長因子（VEGF）水平。結(jié)果 治療后，對照組心絞痛和心電圖療效分別為81.54%和70.77%，而治療組的心絞痛和心電圖療效分別為93.85%和86.15%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者心絞痛發(fā)作頻率和持續(xù)時(shí)間，以及硝酸甘油消耗量、ST段下移幅度和TIB均顯著下降（P<0.05），且治療組的改善效果均顯著優(yōu)于對照組（P<0.05）。治療后，兩組患者SAQ中各維度評分及其總分均顯著升高（P<0.05），且治療組SAQ中除DP外，其他各維度評分及總分均顯著高于對照組（P<0.05）。治療后，兩組患者血清MPO、NT-proBNP、VEGF濃度均顯著降低（P<0.05）；且治療組比對照組下降更顯著（P<0.05）。結(jié)論 心脈通膠囊聯(lián)合曲美他嗪治療不穩(wěn)定型心絞痛的整體療效良好，能明顯改善患者心絞痛發(fā)作情況，保護(hù)心臟功能，逆轉(zhuǎn)病情，提高患者生命質(zhì)量。

Objective To investigate the clinical effect of Xinmaitong Capsules combined with trimetazidine in treatment of unstable angina pectoris. Methods Patients (130 cases) with unstable angina pectoris in Weinan Central Hospital from July 2016 to July 2019 were randomly divided into control (65 cases) and treatment (65 cases) groups. Patients in the control group were po administered with Trimetazidine Hydrochloride Tablets during the meal, 20 mg/time, three times daily. Patients in the treatment group were po administered with Xinmaitong Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the angina pectoris attack, TIB, SAQ scores, and the serum level of MPO, NT-proBNP and VEGF in two groups before and after treatment were compared. Results After treatment, the therapeutic efficacy of angina pectoris and electrocardiogram efficacy in the control group were 81.54% and 70.77%, which were significantly lower than 93.85% and 86.15% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the frequency and duration of angina, consumption of nitroglycerin, ST segment down range and TIB in two groups were significantly decreased (P<0.05), and the improvement effect of these indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the scores of all dimensions and total scores in SAQ in two groups were significantly increased (P<0.05), and these scores except DP in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the serum level of MPO, NT-proBNP and VEGF in two groups was significantly decreased (P<0.05), and which in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Xinmaitong Capsules combined with trimetazidine in treatment of unstable angina pectoris has a good overall curative effect, can obviously improve the attack of angina pectoris, protect cardiac function, reverse the disease and improve the quality of life of patients.

R972